Thulium laser transurethral vaporesection of the prostate versus transurethral resection of the prostate for men with lower urinary tract symptoms or urinary retention (UNBLOCS): a randomised controlled trial

Abstract

Summary Background Transurethral resection of the prostate (TURP) is the standard operation for benign prostatic obstruction. Thulium laser transurethral vaporesection of the prostate (ThuVARP) is a technique with suggested advantages over TURP, including reduced complications and hospital stay. We aimed to investigate TURP versus ThuVARP in men with lower urinary tract symptoms or urinary retention secondary to benign prostatic obstruction. Methods In this randomised, blinded, parallel-group, pragmatic equivalence trial, men in seven UK hospitals with bothersome lower urinary tract symptoms or urinary retention secondary to benign prostatic obstruction were randomly assigned (1:1) at the point of surgery to receive ThuVARP or TURP. Patients were masked until follow-up completion. Centres used their usual TURP procedure (monopolar or bipolar). All trial surgeons underwent training on the ThuVARP technique. Co-primary outcomes were maximum urinary flow rate (Qmax) and International Prostate Symptom Score (IPSS) at 12-months post-surgery. Equivalence was defined as a difference of 2·5 points or less for IPSS and 4 mL per s or less for Qmax. Analysis was done according to the intention-to-treat principle. The trial is registered with the ISRCTN Registry, ISRCTN00788389. Findings Between July 23, 2014, and Dec 30, 2016, 410 men were randomly assigned to ThuVARP or TURP, 205 per study group. TURP was superior for Qmax (mean 23·2 mL per s for TURP and 20·2 mL per s for ThuVARP; adjusted difference in means −3·12, 95% CI −5·79 to −0·45). Equivalence was shown for IPSS (mean 6·3 for TURP and 6·4 for ThuVARP; adjusted difference in means 0·28, −0·92 to 1·49). Mean hospital stay was 48 h in both study groups. 91 (45%) of 204 patients in the TURP group and 96 (47%) of 203 patients in the ThuVARP group had at least one complication. Interpretation TURP and ThuVARP were equivalent for urinary symptom improvement (IPSS) 12-months post-surgery, and TURP was superior for Qmax. Anticipated laser benefits for ThuVARP of reduced hospital stay and complications were not observed. Funding UK National Institute for Health Research Health Technology Assessment Programme.

Differences in surgical and functional outcomes in benign prostate hyperplasia patients with only lower urinary tract symptoms versus those in retention: A systematic review and meta‐analysis

“…The remaining 91 papers were further assessed to exclude studies with the same population and different follow‐up. Finally, 25 studies including 1 RCT parallel study, 11 prospective single arm study, and 13 retrospective studies, were identified for meta‐analysis 12–36 . Figure 1 shows the PRISMA flow diagram.…”

Pharmacological and interventional treatment of benign prostatic obstruction: An evidence‐based comparative review

“…HoLEP has been highly scrutinized with level 1 evidence to suggest that it provides at least equivalent if not better improvement A recent RCT also failed to demonstrate any difference in efficacy or safety between TURP and Thulium laser vaporesection of the prostate (ThuVARP). 162 The retreatment rate of HoLEP has been reported at 0% in a long-term outcome study of an RCT with 7 years of follow-up, 163 compared with 1%-2% per year when treated with monopolar TURP. 1…”

Modern advancements in minimally invasive surgical treatments for benign prostatic obstruction

“…Of note, only 24% of patients without sexual dysfunction at baseline developed sexual dysfunction 12 months post-surgery. 12 …”